# A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

> **NCT04490590** · PHASE4 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 30 (estimated)

## Conditions studied

- NK/T-Cell Lymphoma

## Interventions

- **DRUG:** Chidamide+ Etoposide

## Key facts

- **NCT ID:** NCT04490590
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04490590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04490590, "A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04490590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*